Effectively Securing Cell And Gene Therapies With Closed Systems
By Jayanthi Grebin, Sr. Business Development Manager CGT at CPC - Colder Products Company
The cell and gene therapy (CGT) industry is growing rapidly, due to their potential to target chronic and rare diseases that previously had limited treatment options. Yet, there are many challenges to developing these innovative new therapies that cannot be addressed using traditional manufacturing models and processes. Historically, these therapies are produced for small patient populations in clinical trials using laboratory scale equipment and utilizing manual, open processes completed under laminar hoods. An increased focus on efficiency and flexibility from the biopharmaceutical industry has accelerated the adoption of novel technologies and solutions to manufacture cell and gene therapies. Among these advancements is the implementation of a closed system design utilizing single-use technology (SUT).
Using Single-Use Connectors To Increase The Integrity Of Closed Systems
Laminar Flow Hood
Considering the inherent complexity of biologic development and manufacturing and the added business pressures of biopharma’s challenging landscape, the margin for error in today’s industry is small. That is why minimizing the threat of contamination using a closed system during drug development and manufacturing is critical. Yet, the traditional method for connecting each step in a closed process may present other risks to the integrity of your product. Therefore, it is important you have confidence that the single-use sterile connectors you select meet the sterility and reliability needs of your particular application.
Bridging The Connectivity Gap Between Traditional Sensors And Single-Use Systems
By Julie Stiller, Application Development Manager, David Koechlein, Application Development Manager, and Derek Pendlebury, Global Sales Director, Colder Products Company
Critical process parameters (CPPs) are the key variables in the pharmaceutical manufacturing process that are most likely to affect the quality attributes of a biological product. CPPs must be monitored and controlled throughout the various stages of production. For example, in the production of recombinant proteins, the cell culture expansion and production steps require continuous real-time monitoring and control. Any deviations in CPPs from the historical data gathered during the process development steps could negatively impact cell growth and, therefore, product yield. They can also potentially affect the drug’s overall safety and efficacy. The most common CPPs measured are pH, dissolved oxygen, capacitance, and biomass. Another
By Nick Johnson, CPC
Biopharmaceutical engineers are frequently tasked with finding new and improved ways to efficiently manufacture at scale. Historically, implementing and validating new systems and processes proved a considerable challenge, making the prospect of upgrading bioproduction equipment daunting, disruptive, and expensive.
Today, however, demand for more has them researching ways to scale up and transfer larger volumes of product through the bioproduction process as quickly and easily as possible while maintaining a high-quality standard, sterility, and of course no loss of product. High-flow sterile connectors make upgrading or upscaling bioproduction more reliable, efficient, and rewarding than ever. A new generation of large, high-flow, and genderless sterile connectors – the AseptiQuik® Large Format (AQL) series from Colder Products Company (CPC) – offers functionality and ease of use benefits that help engineers derive the most value from their manufacturin
New Blind Mate Connector Offers Secure Liquid Cooling Connections
Allows disconnection under pressure without drips, protecting electronics from exposure to fluid
Enables system designers to increase their power and/or density
Original Press Release:
CPC Combines Excellent Flow Rates with Blind-Mate Convenience in a Lighter Weight Coupling
Downers Grove, Ill., Dec. 9, 2020 /PRNewswire/ CPC (Colder Products Company), part of Dover (NYSE: DOV) and maker of quick disconnects (QDs) designed specifically for liquid cooling of electronics, has expanded its BLQ Series with the new Everis™ BLQ6 blind mate connector. The Everis BLQ6 latchless connector achieves 3/8″ flow and a Cv of ~2.2 for high-performance liquid cooling. Specifically designed for rack and panel configurations, the chamfer design and connection tolerances are ideal for applications where operators have obstructed views to connections and disconnections yet still require connection assurance.